EA201500579A1 - Комбинированная терапия с использованием воласертиба - Google Patents

Комбинированная терапия с использованием воласертиба

Info

Publication number
EA201500579A1
EA201500579A1 EA201500579A EA201500579A EA201500579A1 EA 201500579 A1 EA201500579 A1 EA 201500579A1 EA 201500579 A EA201500579 A EA 201500579A EA 201500579 A EA201500579 A EA 201500579A EA 201500579 A1 EA201500579 A1 EA 201500579A1
Authority
EA
Eurasian Patent Office
Prior art keywords
volasertiba
combined therapy
volasertib
cytarabine
csf
Prior art date
Application number
EA201500579A
Other languages
English (en)
Inventor
Тилльманн Таубе
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201500579A1 publication Critical patent/EA201500579A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)

Abstract

В изобретении описано применение воласертиба или его соли или гидрата для лечения пациентов, страдающих от острого миелолейкоза, которое заключается в том, что пациенту вводят высокие дозы воласертиба в комбинации с флударабином, цитарабином и гранулоцитарным колониестимулирующим фактором (ГКСФ) или в комбинации с флударабином, цитарабином, ГКСФ и липосомальной формой цитрата даунорубицина для инъекций.
EA201500579A 2012-11-30 2013-11-27 Комбинированная терапия с использованием воласертиба EA201500579A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195162 2012-11-30
PCT/EP2013/074862 WO2014083058A1 (en) 2012-11-30 2013-11-27 Combination therapy with volasertib

Publications (1)

Publication Number Publication Date
EA201500579A1 true EA201500579A1 (ru) 2015-12-30

Family

ID=47325907

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500579A EA201500579A1 (ru) 2012-11-30 2013-11-27 Комбинированная терапия с использованием воласертиба

Country Status (15)

Country Link
US (2) US20140154304A1 (ru)
EP (1) EP2925343A1 (ru)
JP (1) JP2016501208A (ru)
KR (1) KR20150090091A (ru)
CN (1) CN104812400A (ru)
AU (1) AU2013351180A1 (ru)
BR (1) BR112015011748A2 (ru)
CA (1) CA2889787A1 (ru)
CL (1) CL2015001258A1 (ru)
EA (1) EA201500579A1 (ru)
IL (1) IL238174A0 (ru)
IN (1) IN2015DN03075A (ru)
MX (1) MX2015006592A (ru)
PH (1) PH12015501113A1 (ru)
WO (1) WO2014083058A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104306336B (zh) * 2014-11-18 2016-08-24 河北天成药业股份有限公司 枸橼酸柔红霉素脂质体注射液的制备工艺
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008778B1 (ru) 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
RU2474427C2 (ru) * 2006-12-20 2013-02-10 Универзитетсклиникум Хамбург-Эппендорф Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей
SI3300601T1 (sl) * 2007-02-16 2022-05-31 Rotalec Ip Holdings Llc Fiksna razmerja med zdravili za zdravljenje vrst hematopoetskega raka in proliferativnih motenj
US9358233B2 (en) * 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia

Also Published As

Publication number Publication date
EP2925343A1 (en) 2015-10-07
IL238174A0 (en) 2015-05-31
WO2014083058A1 (en) 2014-06-05
PH12015501113A1 (en) 2015-08-17
KR20150090091A (ko) 2015-08-05
BR112015011748A2 (pt) 2017-07-11
CA2889787A1 (en) 2014-06-05
US20140154304A1 (en) 2014-06-05
CN104812400A (zh) 2015-07-29
JP2016501208A (ja) 2016-01-18
AU2013351180A1 (en) 2015-04-30
IN2015DN03075A (ru) 2015-10-02
US20170173023A1 (en) 2017-06-22
CL2015001258A1 (es) 2015-10-02
MX2015006592A (es) 2015-08-05

Similar Documents

Publication Publication Date Title
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2016090024A3 (en) Combination therapy for treatment of cancer
TW201613578A (en) Pharmaceutical combinations
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
NZ720273A (en) Preparations and methods for treating a gd2 positive cancer
WO2015035410A8 (en) Cancer therapy
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
EA201500579A1 (ru) Комбинированная терапия с использованием воласертиба
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.